Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desloratadine Citrate Disodium Oral Solution in Pediatric Urticaria and Allergic Rhinitis
CTR20230493Phase 2Completed
- Sponsor
- Hefei Enruite Pharmaceutical
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of desloratadine in acute urticaria, chronic urticaria (CU) and allergic rhinitis (AR), sponsored by Hefei Enruite Pharmaceutical. Primary endpoints: Absorption rate constant (Ka), Apparent clearance (CL/F) and 1 more. Started Feb 2023; status: completed.
02
Drugs
desloratadine
03
Conditions
acute urticariachronic urticaria (CU)allergic rhinitis (AR)
Beyond the preview
Go deeper on CTR20230493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230493.